Use of lidocaine patches for neuropathic pain in a comprehensive cancer centre

Pain Research and Management

Volumn 14, Issue 5, 2009, Pages 381-388

  Fleming, Julia Ann ^a   O'Connor, Bradley David ^b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b NORTHERN HOSPITAL   (Australia)

Author keywords

Audit; Lidocaine 5 patch; Neuropathic cancer pain

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; CLONIDINE; CORTICOSTEROID; GABAPENTIN; LIDOCAINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PARACETAMOL; PREGABALIN; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGED; ALLODYNIA; APPLICATION SITE ERYTHEMA; ARTICLE; CANCER CENTER; CANCER PAIN; CHRONIC PAIN; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG INTERMITTENT THERAPY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECZEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHIC PAIN; PAIN; PARESTHESIA; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PRURITUS; RETROSPECTIVE STUDY; SKIN IRRITATION; TRANSDERMAL PATCH; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 73249118286     PISSN: 12036765     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/723179     Document Type: Article

References (52)

1. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. Pain 1999;82:263-74.
2. Fainsinger RL, Nekolaichuk CL, Lawlor PG, Neumann CM, Hanson J, Vigano A. A multicenter study of the revised Edmonton Staging System for classifying cancer pain in advanced cancer patients. J Pain Symptom Manage 2005;29:224-37.
3. Scottish Intercollegiate Guidelines Network. SIGN 106: Control of pain in adults with cancer. 〈http://www.sign.ac.uk/〉 (Version current at November 5, 2008).
4. National Comprehensive Cancer Network, Inc. NCCN Clinical Practice Guidelines in Oncology - V.1.2009: Adult Cancer Pain. 〈http://www.nccn.org/ 〉 (Version current at March 16, 2009).
5. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007;132:237-51.
6. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: Double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996;65;39-44.
7. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: Results of an enriched enrollment study. Pain 1999;80:533-8.
8. Comer AM, Lamb HM. Lidocaine patch 5%. Drugs 2000;59:245-9.
9. Campbell BJ, Rowbotham M, Davies PS, Jacob P III, Benowitz NL. Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci 2002;91:1343-50.
10. Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: A review of the literature. J Clin Pharmacol 2003;43:111-7.
11. Sinnott C. Problems recruiting cancer patients to a comparative clinical trial of drug treatments for neuropathic pain in palliative care. J Pain Symptom Manage 2002;23:270-2.
12. Cheville AL, Sloan JA, Northfelt DW, et al. Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: A phase III double-blind crossover study (N01CB). Support Care Cancer 2009;17:451-60.
13. Ellison N, Loprinzi CL, Kugler J, et al. Phase III placebo-controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients. J Clin Oncol 1997;15:2974-80.
14. Bruera E, Ripamonti C, Brenneis C, Macmillan K, Hanson J. A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain. J Pain Symptom Manage 1992;7:138-40.
15. Ellemann K, Sjogren P, Banning AM, Jensen TS, Smith T, Geertsen P. Trial of intravenous lidocaine on painful neuropathy in cancer patients. Clin J Pain 1989;5:291-4.
16. Kalso E, Tasmuth T, Neuvonen PJ. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain 1996;64:293-302.
17. Tasmuth T, Hartel B, Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 2002;6:17-24.
18. Mercadante S, Arcuri E, Tirelli W, Villari P, Casuccio A. Amitriptyline in neuropathic cancer pain in patients on morphine therapy: A randomized placebo-controlled, double-blind crossover study. Tumori 2002;88:239-42.
19. Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain: A randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 2004;22:2909-17.
20. Wiffen PJ, Rees J. Lamotrigine for acute and chronic pain. Cochrane Database Syst Rev 2007:CD006044.
21. Keskinbora K, Pekel AF, Aydinli I. Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: A randomized open trial. J Pain Symptom Manage 2007;34:183-9.
22. Arbaiza D, Vidal O. Tramadol in the treatment of neuropathic cancer pain: A double-blind, placebo-controlled study. Clin Drug Investig 2007;27:75-83.
23. Roos DE, Turner SL, O'Brien PC, et al. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). Radiother Oncol 2005;75:54-63.
24. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: A randomized, double-blind, placebo-controlled study. Pain 2003;106:151-8.
25. Galer BS. Effectiveness and safety of lidocaine patch 5%. J Fam Pract 2002;51:867-8.
26. Nalamachu S, Crockett RS, Mathur D. Lidocaine patch 5 for carpal tunnel syndrome: How it compares with injections: A pilot study. J Fam Pract 2006;55:209-14.
27. Lin PL, Fan SZ, Huang CH, et al. Analgesic effect of lidocaine patch 5% in the treatment of acute herpes zoster: A double-blind and vehicle-controlled study. Reg Anesth Pain Med 2008;33:320-5.
28. Nayak S, Cunliffe M. Lidocaine 5% patch for localized chronic neuropathic pain in adolescents: Report of five cases. Paediatr Anaesth 2008;18:554-8.
29. Desai MJ, Siriki R, Wang D. Treatment of pain in Dercum's disease with Lidoderm (lidocaine 5% patch): A case report. Pain Med 2008;9:1224-6.
30. Karmarkar A, Lieberman I. Management of complex regional pain syndrome type II using lidoderm 5% patches. Br J Anaesth 2007;98:261-2.
31. Herrmann DN, Barbano RL, Hart-Gouleau S, Pennella-Vaughan J, Dworkin RH. An open-label study of the lidocaine patch 5% in painful idiopathic sensory polyneuropathy. Pain Med 2005;6:379-84.
32. Gimbel J, Linn R, Hale M, Nicholson B. Lidocaine patch treatment in patients with low back pain: Results of an open-label, nonrandomized pilot study. Am J Ther 2005;12:311-9.
33. Davis MD, Sandroni P. Lidocaine patch for pain of erythromelalgia: Follow-up of 34 patients. Arch Dermatol 2005;141:1320-1.
34. Galer BS, Gammaitoni AR, Oleka N, Jensen MP, Argoff CE. Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain. Curr Med Res Opin 2004;20(Suppl 2):S5-12.
35. Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA, Dworkin RH. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004;61:914-8.
36. White WT, Patel N, Drass M, Nalamachu S. Lidocaine patch 5% with systemic analgesics such as gabapentin: A rational polypharmacy approach for the treatment of chronic pain. Pain Med 2003;4:321-30.
37. Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev 2007:CD004846.
38. Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain 1996;67:241-51.
39. Dworkin RH, Gnann JW Jr, Oaklander AL, Raja SN, Schmader KE, Whitley RJ. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain 2008;9(1 Suppl 1):S37-44.
40. Foss JM, Apkarian AV, Chialvo DR. Dynamics of pain: Fractal dimension of temporal variability of spontaneous pain differentiates between pain states. J Neurophysiol 2006;95:730-6.
41. Persaud N, Strichartz GR. Micromolar lidocaine selectively blocks propagating ectopic impulses at a distance from their site of origin. Pain 2002;99:333-40.
42. Wasner G, Kleinert A, Binder A, Schattschneider J, Baron R. Postherpetic neuralgia: Topical lidocaine is effective in nociceptor-deprived skin. J Neurol 2005;252:677-86.
43. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: Risk factors and prevention. Lancet 2006;367:1618-25.
44. Hans GH, Robert DN, Van Maldeghem KN. Treatment of an acute severe central neuropathic pain syndrome by topical application of lidocaine 5% patch: A case report. Spinal Cord 2008;46:311-3.
45. Wasner G, Naleschinski D, Baron R. A role for peripheral afferents in the pathophysiology and treatment of at-level neuropathic pain in spinal cord injury? A case report. Pain 2007;131:219-25.
46. Geha PY, Baliki MN, Chialvo DR, Harden RN, Paice JA, Apkarian AV. Brain activity for spontaneous pain of postherpetic neuralgia and its modulation by lidocaine patch therapy. Pain 2007;128:88-100.
47. Mackley CL, Marks JG Jr, Anderson BE. Delayed-type hypersensitivity to lidocaine. Arch Dermatol 2003;139:343-6.
48. Handfield-Jones SE, Cronin E. Contact sensitivity to lignocaine. Clin Exp Dermatol 1993;18:342-3.
49. Thyssen JP, Menne T, Elberling J, Plaschke P, Johansen JD. Hypersensitivity to local anaesthetics - update and proposal of evaluation algorithm. Contact Dermatitis 2008;59:69-78.
50. Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol 1995;37:246-53.
51. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: The Neuropathic Pain Scale. Neurology 1997;48:332-8.
52. Jensen MP, Dworkin RH, Gammaitoni AR, Olaleye DO, Oleka N, Galer BS. Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain Scale. J Pain 2005;6:98-106.